Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name MAP2K1 K57N
Gene Variant Detail

MAP2K1 K57N (gain of function)

Relevant Treatment Approaches MEK inhibitor (Pan) MEK1 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02747537 Phase II Irinotecan + Sorafenib Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan Withdrawn 0
NCT01781429 Phase Ib/II Ulixertinib Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Completed USA 0
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT04252339 Phase I RLY-1971 RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT05221320 Phase II Hydroxychloroquine + Ulixertinib Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Recruiting USA 0
NCT04488003 Phase II Ulixertinib Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Recruiting USA 0
NCT04145297 Phase I Hydroxychloroquine + Ulixertinib Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH) Recruiting USA 0
NCT04566393 Expanded access Ulixertinib Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies Available USA 0
NCT03087071 Phase II Panitumumab Panitumumab + Trametinib Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer Recruiting USA 0
NCT02607813 Phase I LXH 254 + Spartalizumab LXH 254 Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations Completed USA | ITA | FRA | ESP | DEU | CAN 4
NCT01885195 Phase II Binimetinib MEK162 for Patients With RAS/RAF/MEK Activated Tumors Completed USA 0
NCT04616183 Phase Ib/II Abemaciclib + Cetuximab + LY3214996 Cetuximab + LY3214996 LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Recruiting USA 0
NCT04534283 Phase II Abemaciclib + LY3214996 A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. Recruiting USA 0
NCT03181100 Phase II Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Recruiting USA 0
NCT04418167 Phase I JSI-1187 Dabrafenib + JSI-1187 JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations Recruiting USA 0
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA 1